Compare · BWAY vs DXCM
BWAY vs DXCM
Side-by-side comparison of BrainsWay Ltd. (BWAY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BWAY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 47.0x BWAY ($629.7M).
- Over the past year, BWAY is up 159.2% and DXCM is down 8.8% - BWAY leads by 168.0 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 5 for BWAY).
- Company
- BrainsWay Ltd.
- DexCom Inc.
- Price
- $15.68+6.31%
- $76.65-1.74%
- Market cap
- $629.7M
- $29.58B
- 1M return
- +11.60%
- +4.76%
- 1Y return
- +159.17%
- -8.79%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2005
- News (4w)
- 4
- 4
- Recent ratings
- 5
- 25
BrainsWay Ltd.
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BWAY
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
- Chief Technology Officer Moiseyev Gilad converted options into 7,500 units of Ordinary Shares, covered exercise/tax liability with 1,902 units of Ordinary Shares and sold 5,000 units of Ordinary Shares, increasing direct ownership by 1% to 53,098 units (SEC Form 4)
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
- Chief Scientist Roth Yiftach sold 7,000 units of Ordinary Shares, decreasing direct ownership by 0.65% to 1,072,305 units (SEC Form 4)
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)